Business
Biostatistical services provider for clinical trials since 1991.
IDDI is a CDISC Associate Member.
Founded
Brussels (Belgium),1991, (ID²)
Mission
The mission of IDDI is to deliver clinical trials results that are scientifically accurate, validated and reproducible.
Main therapeutic areas
- Oncology
- Ophthalmology
- Infectious Diseases
- Cardiovascular
Other significant therapeutic areas:
Medical Devices, Nutrition, Dermatology, Gastroenterology, Gynecology, Genito-Urinary, Musculoskeletal, Haematology, Immunology, Neurology.
Services
Web systems
- ID-net™, a web based centralized randomization and treatment allocation system.
- ID-supply™ , a centralized drug supply management system.
- ID-code™, a coding and validation system based on the MedDRA® and WHO-DRUG dictionaries.
- TrialControl™, an eRoom with access to key trial information.
Management and Staff
- Damien Tremolet, Chief Executive Officer
- Joël Dequenne, MBA, Chief Financial Officer
- Catherine Indekeu, MBA, Vice President, Business Development
- Linda Danielson, MSc, Vice President, Biostatistical Services
- Judith De Kempeneer, Vice President, Projects and Contracts
- Marie-Pierre Debroas, Director HR and Administration
IDDI Team of Consultants
Dr Buyse leads a team of consultants, aimed at providing pharmaceutical and biotechnology companies, as well as clinical cooperative groups and contract research organizations, with biostatistical support for clinical development. The team of experts also includes Professor Tomasz Burzykowski, VP of Research at IDDI
Locations
- Louvain-la-Neuve, Belgium (Headquarters)
- Saint Germain-en-Laye, France
- Cambridge, MA, USA
History
1991: BRUSSELS, BELGIUM : The International Institute for Drug Development (ID²) was established in Brussels in 1991 by a team of experts in clinical trials, biostatistics, and biomedical computing.
1996: PARIS, FRANCE: The company expanded with the opening of an office in Paris. The company offered data management services out of its Paris office and biostatistical services out of its headquarters in Brussels.
2001: CAMBRIDGE, MA, USA: The company was renamed IDDI and opened an office in Cambridge, MA, to offer sophisticated web-based services for clinical trials supported by a dedicated help desk on both sides of the Atlantic Ocean.
Today: With over 20 years experience, IDDI is appreciated as a valuable partner in the design, conduct and analysis of clinical trials through optimal design, innovative methodology and state-of-the-art technology that help achieve time savings and cost-effective clinical trial processes.
Quality Assurance
IDDI is committed to maintaining the highest ethical standards, which are cornerstone of the reputation built over the past two decades. IDDI employees must also adhere to these high standards which ensure IDDI's integrity.
The development of computer technology, bioscience, and biotechnology during the last thirty years exerted as a tremendous influence on medicine. The Declaration of Helsinki adopted by the World Medical Association in 1964 and revised in 1983, 2000 and 2008 has established guidelines to safeguard humans used as subjects in medical experiments.
IDDI also bases quality on other specific standards and regulations issued by ICH, FDA, EMEA, and other national or international legislations (European, Belgian, American,...). These principles are incorporated within the company's Quality System that is to be understood, implemented and maintained throughout the organization.
IDDI QA department aims to continuously maintain this Quality System up to date and in alignment with the customers' requirements.
